« Previous
Next »
The American Journal of Medicine
Volume 122, Issue 10
, Pages 955-960
, October 2009
Appropriateness of Collaborations between Industry and the Medical Profession: Physicians' Perceptions
References
- . Relationships with the drug industry: keep at arm's length. BMJ. 2009;338:b222
- . Opinion 8.061: Gifts to Physicians from Industry. http://www.ama-assn.org/ama/pub/category/4001.htmlMarch 2008;Accessed August 5, 2008
- . Industry Funding of Medical Education (Report of an AAMC Task Force). Washington, DC: Association of American Medical Colleges; 2008;
- . Code of ethics on interactions with health care professionals. http://www.advamed.org/NR/rdonlyres/61D30455-F7E9-4081-B219-12D6CE347585/0/AdvaMedCodeofEthicsRevisedandRestatedEffective20090701.pdfDecember 2008;Accessed April 5, 2009
- . Code on interactions with healthcare professionals. http://www.phrma.org/files/PhRMA%20Marketing%20Code%202008.pdfJuly 2008;Accessed April 5, 2009
- . A national survey of physician-industry relationships. N Engl J Med. 2007;356:1742–1750
- . Are gifts from pharmaceutical companies ethically problematic? (A survey of physicians). Arch Intern Med. 2003;163:2213–2218
- . Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med. 2001;110:551–557
- . A prospective before-and-after trial of an educational intervention about pharmaceutical marketing. Acad Med. 2004;79:1046–1050
- Residents' perceptions over time of pharmaceutical industry interactions and gifts and the effect of an educational intervention. Acad Med. 2006;81:595–602
- . WAME Policy Statements: authorship. http://www.wame.org/resources/policies#authorshipJanuary 10, 2007;Accessed July 9, 2008
- In: DeMets DL, Friedman LM, Furberg CD editor. Data Monitoring in Clinical Trials: A Case-studies Approach. New York, NY: Springer Publishing Co; 2005;
- . Impugning the integrity of medical science: the adverse effects of industry influence. JAMA. 2008;299:1833–1835
- . Prestige paradox: high pay doesn't necessarily equal high prestige. http://www.harrisinteractive.com/harris_poll/index.asp?PID=939Accessed December 12, 2008
Funding: Data collection for this work was partially supported by the Attorney General Consumer and Prescriber Grant Program administered by the State of Oregon. Dr. Ross was compensated for his work as a consultant at the request of plaintiffs in litigation against Merck and Co., Inc. related to rofecoxib from 2006-2007.
Conflict of Interest: None.
Authorship: All authors had full access to all the data in the study and a role in writing the manuscript.
PII: S0002-9343(09)00501-4
doi: 10.1016/j.amjmed.2009.04.013
« Previous
Next »
The American Journal of Medicine
Volume 122, Issue 10
, Pages 955-960
, October 2009

